<DOC>
	<DOC>NCT01773785</DOC>
	<brief_summary>The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.</brief_summary>
	<brief_title>Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirmed biliary tract or gallbladder cancer that have relapsed or are refractory after one prior gemcitabinebased chemotherapy regimen for advanced biliary cancer Evaluable disease ECOG PS ≤ 2 Adequate bone marrow, liver and renal function Treatment with more than one prior chemotherapy regimen Known, uncontrolled CNS metastases Baseline peripheral neuropathy ≥ grade 2. Significant circulatory disorders in the past 6 months Concomitant use of phosphodiesterase inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>